What are the onset, peak, and duration of action of Humalog Mix 25 (insulin lispro protamine suspension)?

Humalog Mix 25 Pharmacokinetic Profile

Humalog Mix 25 (25% insulin lispro/75% insulin lispro protamine suspension) has a rapid onset of action within 15 minutes, reaches peak serum concentrations at 30-240 minutes (median 60 minutes), and maintains glucose-lowering activity for over 23 hours. 1

Onset of Action

• The rapid-acting component (insulin lispro) begins working within 15 minutes of subcutaneous injection 1, 2
• This rapid onset is maintained in the Mix 25 formulation due to the 25% insulin lispro component 1
• The formulation demonstrates significantly earlier maximum pharmacodynamic response compared to NPH-based insulins 3

Peak Effect

• Peak serum insulin concentrations occur between 30-240 minutes after injection, with a median of 60 minutes 1
• The biphasic absorption profile creates two distinct phases:
  • Early phase: Represents the rapid-acting insulin lispro component with peak activity at 1-2 hours 1
  • Late phase: Represents the prolonged action of insulin lispro protamine suspension 1
• Maximum glucose-lowering activity (Rmax) is significantly greater than insulin glargine or detemir 3

Duration of Action

• Duration of glucose-lowering activity exceeds 23 hours in most patients 3
• Following a 0.8 U/kg dose, approximately 48% of patients achieve a full 24 hours of glucose-lowering activity 3
• The duration is comparable to intermediate-acting insulins like NPH 70/30 1
• As with other intermediate-acting insulins, a meaningful terminal half-life cannot be calculated due to the prolonged absorption of the protamine suspension component 1

Clinical Implications

The pharmacodynamic profile makes Humalog Mix 25 suitable for twice-daily administration before breakfast and dinner 4, though some evidence suggests once-daily dosing may be feasible in type 2 diabetes 3.

Key Advantages:

• Can be administered immediately before meals (within 15 minutes), unlike regular insulin mixtures requiring 30-45 minute pre-meal timing 5, 6
• Provides better postprandial glucose control compared to human insulin 30/70 mixtures 5, 7
• Reduced nocturnal hypoglycemia risk when given before evening meals compared to human insulin 30/70 5

Important Caveats:

• Individual variability exists: The time course of action may vary considerably between patients and within the same patient 1
• Site of injection, exercise, and other variables affect absorption rate and onset 1
• The parameters should be considered general guidelines rather than absolute values 1
• Cannot be mixed with other insulins due to the protamine formulation 8